Skip to content
CancerIndex

Publication

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors not recorded

Cancer Res2014PMID 24576830PMC4005042stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
24576830
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF V600E1
Mirdametinib + TrametinibSubstitutesMelanomaPredictiveDDoes Not Support Resistance3accepted
EID86

In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.

PMID 24576830 · Nissan et al., 2014 · Open in CIViC

civic
BRAF V600E + NF1 LossBRAFNF11
VemurafenibMelanomaPredictiveDSupports Resistance3accepted
EID90

In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.

PMID 24576830 · Nissan et al., 2014 · Open in CIViC

civic